Literature DB >> 11876760

Age-dependent preference in human antibody responses to Streptococcus pneumoniae polypeptide antigens.

S Lifshitz1, R Dagan, M Shani-Sekler, N Grossman, G Fleminger, M Friger, Y Mizrachi Nebenzahl.   

Abstract

Vulnerability to Streptococcus pneumoniae is most pronounced in children. The microbial virulence factors and the features of the host immune response contributing to this phenomenon are not completely understood. In the current study, the humoral immune response to separated Strep. pneumoniae surface proteins and the ability to interfere with Strep. pneumoniae adhesion to cultured epithelial cells were analysed in adults and in children. Sera collected from healthy adults recognized Strep. pneumoniae separated lectin and nonlectin surface proteins in Western blot analysis and inhibited on average 80% of Strep. pneumoniae adhesion to epithelial cells in a concentration-dependent manner. However, sera longitudinally collected from healthy children attending day care centres from 18 months of age and over the course of the following 2 years revealed: (a) development of antibodies to previously unrecognized Strep. pneumoniae surface proteins with age; (b) a quantitative increase in antibody responses, measured by densitometry, towards separated Strep. pneumoniae surface proteins with age; and (c) inhibition of Strep. pneumoniae adhesion to epithelial cells, which was 50% on average at 18 months of age, increased significantly to an average level of 80% inhibition at 42 months of age equalling adult sera inhibitory values. The results obtained in the current study, from the longitudinally collected sera from healthy children with documented repeated Strep. pneumoniae colonization, show that repeated exposures are insufficient to elicit an immune response to Strep. pneumoniae proteins at 18 months of age. This inability to recognize Strep. pneumoniae surface proteins may stem from the inefficiency of T-cell-dependent B-cell responses at this age and/or from the low immunogenicity of the proteins.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11876760      PMCID: PMC1906324          DOI: 10.1046/j.1365-2249.2002.01745.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  46 in total

1.  Molecular and cellular mechanisms for microbial entry into the CNS.

Authors:  J R Zhang; E Tuomanen
Journal:  J Neurovirol       Date:  1999-12       Impact factor: 2.643

2.  Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae.

Authors:  D E Briles; E Ades; J C Paton; J S Sampson; G M Carlone; R C Huebner; A Virolainen; E Swiatlo; S K Hollingshead
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

3.  Molecular localization of variable and conserved regions of pspA and identification of additional pspA homologous sequences in Streptococcus pneumoniae.

Authors:  L S McDaniel; J S Sheffield; E Swiatlo; J Yother; M J Crain; D E Briles
Journal:  Microb Pathog       Date:  1992-10       Impact factor: 3.738

4.  Resistance to both complement activation and phagocytosis in type 3 pneumococci is mediated by the binding of complement regulatory protein factor H.

Authors:  C Neeleman; S P Geelen; P C Aerts; M R Daha; T E Mollnes; J J Roord; G Posthuma; H van Dijk; A Fleer
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

5.  Association of intrastrain phase variation in quantity of capsular polysaccharide and teichoic acid with the virulence of Streptococcus pneumoniae.

Authors:  J O Kim; J N Weiser
Journal:  J Infect Dis       Date:  1998-02       Impact factor: 5.226

6.  Identification and characterization of genes determining receptor binding and pilus length of Escherichia coli type 1 pili.

Authors:  L Maurer; P E Orndorff
Journal:  J Bacteriol       Date:  1987-02       Impact factor: 3.490

7.  Natural development of antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A, and pneumolysin in relation to pneumococcal carriage and acute otitis media.

Authors:  S Rapola; V Jäntti; R Haikala; R Syrjänen; G M Carlone; J S Sampson; D E Briles; J C Paton; A K Takala; T M Kilpi; H Käyhty
Journal:  J Infect Dis       Date:  2000-09-05       Impact factor: 5.226

8.  Specificity of binding of a strain of uropathogenic Escherichia coli to Gal alpha 1----4Gal-containing glycosphingolipids.

Authors:  K Bock; M E Breimer; A Brignole; G C Hansson; K A Karlsson; G Larson; H Leffler; B E Samuelsson; N Strömberg; C S Edén
Journal:  J Biol Chem       Date:  1985-07-15       Impact factor: 5.157

9.  CHEMO-IMMUNOLOGICAL STUDIES ON CONJUGATED CARBOHYDRATE-PROTEINS : II. IMMUNOLOGICAL SPECIFICITY OF SYNTHETIC SUGAR-PROTEIN ANTIGENS.

Authors:  O T Avery; W F Goebel
Journal:  J Exp Med       Date:  1929-09-30       Impact factor: 14.307

10.  Peptide permeases from Streptococcus pneumoniae affect adherence to eucaryotic cells.

Authors:  D R Cundell; B J Pearce; J Sandros; A M Naughton; H R Masure
Journal:  Infect Immun       Date:  1995-07       Impact factor: 3.441

View more
  8 in total

1.  Inhibition of pneumococcal adherence to human nasopharyngeal epithelial cells by anti-PsaA antibodies.

Authors:  Sandra Romero-Steiner; Tamar Pilishvili; Jacquelyn S Sampson; Scott E Johnson; Annie Stinson; George M Carlone; Edwin W Ades
Journal:  Clin Diagn Lab Immunol       Date:  2003-03

2.  Pneumococcal 6-phosphogluconate-dehydrogenase, a putative adhesin, induces protective immune response in mice.

Authors:  D Daniely; M Portnoi; M Shagan; A Porgador; N Givon-Lavi; E Ling; R Dagan; Y Mizrachi Nebenzahl
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

3.  Glycolytic enzymes associated with the cell surface of Streptococcus pneumoniae are antigenic in humans and elicit protective immune responses in the mouse.

Authors:  E Ling; G Feldman; M Portnoi; R Dagan; K Overweg; F Mulholland; V Chalifa-Caspi; J Wells; Y Mizrachi-Nebenzahl
Journal:  Clin Exp Immunol       Date:  2004-11       Impact factor: 4.330

4.  Vaccine-induced human antibodies to PspA augment complement C3 deposition on Streptococcus pneumoniae.

Authors:  Martina M Ochs; William Bartlett; David E Briles; Bryony Hicks; Audra Jurkuvenas; Peggy Lau; Bing Ren; Amanda Millar
Journal:  Microb Pathog       Date:  2007-10-11       Impact factor: 3.738

5.  Immunological reactivity of blood from healthy humans to the rAls3p-N vaccine protein.

Authors:  Beverlie Baquir; Lin Lin; Ashraf S Ibrahim; Yue Fu; Valentina Avanesian; Ang Tu; John Edwards; Brad Spellberg
Journal:  J Infect Dis       Date:  2010-02-01       Impact factor: 5.226

6.  NADH oxidase functions as an adhesin in Streptococcus pneumoniae and elicits a protective immune response in mice.

Authors:  Lena Muchnik; Asad Adawi; Ariel Ohayon; Shahar Dotan; Itai Malka; Shalhevet Azriel; Marilou Shagan; Maxim Portnoi; Daniel Kafka; Hannie Nahmani; Angel Porgador; Jonathan M Gershoni; Johnatan M Gershoni; Donald A Morrison; Andrea Mitchell; Michael Tal; Ronald Ellis; Ron Dagan; Yaffa Mizrachi Nebenzahl
Journal:  PLoS One       Date:  2013-04-08       Impact factor: 3.240

Review 7.  Immunoproteomics: the key to discovery of new vaccine antigens against bacterial respiratory infections.

Authors:  Ruth Dennehy; Siobhan McClean
Journal:  Curr Protein Pept Sci       Date:  2012-12       Impact factor: 3.272

8.  Streptococcus pneumoniae Cell-Wall-Localized Phosphoenolpyruvate Protein Phosphotransferase Can Function as an Adhesin: Identification of Its Host Target Molecules and Evaluation of Its Potential as a Vaccine.

Authors:  Yaffa Mizrachi Nebenzahl; Karin Blau; Tatyana Kushnir; Marilou Shagan; Maxim Portnoi; Aviad Cohen; Shalhevet Azriel; Itai Malka; Asad Adawi; Daniel Kafka; Shahar Dotan; Gali Guterman; Shany Troib; Tali Fishilevich; Jonathan M Gershoni; Alex Braiman; Andrea M Mitchell; Timothy J Mitchell; Nurith Porat; Inna Goliand; Vered Chalifa Caspi; Edwin Swiatlo; Michael Tal; Ronald Ellis; Natalie Elia; Ron Dagan
Journal:  PLoS One       Date:  2016-03-18       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.